{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:11:43Z","timestamp":1787962303106,"version":"build-2784847793"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":152,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The aim was to examine the incidence and pattern of MMF discontinuation associated with abnormal monitoring blood-test results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from people prescribed MMF for common inflammatory conditions in the Clinical Practice Research Datalink were used. Participants were followed from the first MMF prescription. The primary outcome was drug discontinuation with an associated abnormal blood-test result within 60\u2009days. Secondary outcomes were drug discontinuation for any reason and discontinuation associated with severely abnormal blood-test results within 60\u2009days. Multivariable Cox regression was used to examine factors associated with the primary outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The cohort included 992 participants (68.9% female, mean age 51.95\u2009years, 47.1% with SLE) contributing 1885 person-years of follow-up. The incidence of MMF discontinuation associated with any (severely) abnormal blood-test results was 153.46 (21.07) per 1000 person-years in the first year of prescription and 32.39 (7.91) per 1000 person-years in later years. Of those patients prescribed MMF, 11.5% (1.7%) discontinued treatment with any (severely) abnormal blood-test results in the first year of prescription. After this period, a mean of 2.6% (0.7%) of patients discontinued treatment with any (severely) abnormal blood-test results per year. Increased serum creatinine and cytopenia were more commonly associated with MMF discontinuation than elevated liver enzymes. Chronic kidney disease stage\u00a03 or higher was significantly associated with MMF discontinuation with any blood-test abnormalities [adjusted hazard ratio (95% CI) 2.22 (1.47, 3.37)].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>MMF is uncommonly discontinued for blood-test abnormalities and even less often discontinued for severe blood-test abnormalities after the first year of prescription. Consideration can be given to less frequent monitoring after 1\u2009year of treatment, especially in those without chronic kidney disease stage\u00a03 or higher.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkac046","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T13:54:32Z","timestamp":1654178072000},"source":"Crossref","is-referenced-by-count":5,"title":["Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3859-7354","authenticated-orcid":false,"given":"Georgina","family":"Nakafero","sequence":"first","affiliation":[{"name":"Academic Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7181-4042","authenticated-orcid":false,"given":"Matthew J","family":"Grainge","sequence":"additional","affiliation":[{"name":"Lifespan and Population Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Card","sequence":"additional","affiliation":[{"name":"Lifespan and Population Health"},{"name":"Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham , Nottingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2677-1028","authenticated-orcid":false,"given":"Christian D","family":"Mallen","sequence":"additional","affiliation":[{"name":"Primary Care Centre Versus Arthritis, School of Medicine, Keele University , Keele"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Riley","sequence":"additional","affiliation":[{"name":"Primary Care Centre Versus Arthritis, School of Medicine, Keele University , Keele"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"van der Windt","sequence":"additional","affiliation":[{"name":"Primary Care Centre Versus Arthritis, School of Medicine, Keele University , Keele"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P","family":"Fox","sequence":"additional","affiliation":[{"name":"Department of Haematology, Nottingham University Hospitals NHS Trust , Nottingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten W","family":"Taal","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research and Innovation, Translational Medical Sciences, School of Medicine, University of Nottingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad P","family":"Aithal","sequence":"additional","affiliation":[{"name":"Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham , Nottingham"},{"name":"NIHR Nottingham BRC, Nottingham University Hospitals NHS Trust and the University of Nottingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hywel C","family":"Williams","sequence":"additional","affiliation":[{"name":"Centre of Evidence-Based Dermatology, School of Medicine, University of Nottingham , Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0121-4919","authenticated-orcid":false,"given":"Abhishek","family":"Abhishek","sequence":"additional","affiliation":[{"name":"Academic Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"2022061612534565300_rkac046-B1","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"New Engl J Med"},{"key":"2022061612534565300_rkac046-B2","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"New Engl J Med"},{"key":"2022061612534565300_rkac046-B3","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/tri.12554","article-title":"Mycophenolate revisited","volume":"28","author":"van Gelder","year":"2015","journal-title":"Transplant Int"},{"key":"2022061612534565300_rkac046-B4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jaad.2008.08.049","article-title":"Mycophenolate mofetil in dermatology","volume":"60","author":"Orvis","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2022061612534565300_rkac046-B5","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jama.2019.12618","article-title":"Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial","volume":"322","author":"Rathinam","year":"2019","journal-title":"JAMA"},{"key":"2022061612534565300_rkac046-B6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00403-020-02108-8","article-title":"Oral mycophenolate mofetil as a stabilizing treatment for progressive non-segmental vitiligo: results from a prospective, randomized, investigator-blinded pilot study","volume":"313","author":"Bishnoi","year":"2021","journal-title":"Arch Dermatol Res"},{"key":"2022061612534565300_rkac046-B7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2165\/11537460-000000000-00000","article-title":"Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo- or ciclosporin-controlled trials","volume":"30","author":"Schiff","year":"2010","journal-title":"Clin Drug Invest"},{"key":"2022061612534565300_rkac046-B8","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"2022061612534565300_rkac046-B9","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/rheumatology\/kew479","article-title":"BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs","volume":"56","author":"Ledingham","year":"2017","journal-title":"Rheumatology"},{"key":"2022061612534565300_rkac046-B10","author":"British Association for Dermatology"},{"key":"2022061612534565300_rkac046-B11","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum","volume":"48","author":"Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"key":"2022061612534565300_rkac046-B12","author":"Clinical Practice Research Datalink (CPRD)","year":"2022"},{"key":"2022061612534565300_rkac046-B13","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"2022061612534565300_rkac046-B14","first-page":"19","article-title":"Kidney Disease Improving Global Outcomes (KDIGO). Section 2: AKI Definition","volume":"2","year":"2012","journal-title":"Kidney Int Suppl (2011)"},{"key":"2022061612534565300_rkac046-B15","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/nep.13718","article-title":"The impact of age on patient tolerance of mycophenolate following kidney transplantation","volume":"25","author":"Rennie","year":"2020","journal-title":"Nephrology"},{"key":"2022061612534565300_rkac046-B16","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/bcp.13154","article-title":"The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients","volume":"83","author":"Tang","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2022061612534565300_rkac046-B17","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.2215\/CJN.09091209","article-title":"The CLEAR Study: a 5-day, 3-g loading dose of mycophenolate mofetil standard 2-g dosing in renal transplantation","volume":"5","author":"Gourishankar","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022061612534565300_rkac046-B18","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1093\/rheumatology\/keab254","article-title":"What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?","volume":"60","author":"Nakafero","year":"2021","journal-title":"Rheumatology"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkac046\/43933304\/rkac046.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/6\/2\/rkac046\/44105586\/rkac046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/6\/2\/rkac046\/44105586\/rkac046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T12:54:04Z","timestamp":1655384044000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkac046\/6598847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkac046","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022]]},"published":{"date-parts":[[2022]]},"article-number":"rkac046"}}